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Interaction effects of 
polyfluoroalkyl substances and 
sex steroid hormones on asthma 
among children
Yang Zhou1, Li-Wen Hu1, Zhengmin (Min) Qian2, Sarah Dee Geiger3, Katelyn L. Parrish2, 
Shyamali C. Dharmage4, Brittany Campbell4, Marjut Roponen5, Pasi Jalava5, Maija-Riitta 
Hirvonen5, Joachim Heinrich  6, Xiao-Wen Zeng1, Bo-Yi Yang1, Xiao-Di Qin1, Yungling Leo 
Lee7 & Guang-Hui Dong1
To evaluate the interactions between polyfluoroalkyl substances (PFASs) and reproductive hormones 
and associated asthma, a total of 231 asthmatic and 225 non-asthmatic adolescents were selected 
from northern Taiwan in the Genetic and Biomarkers study for Childhood Asthma from 2009–2010. 
The interaction between PFASs and reproductive hormones on asthma was analyzed with a two-level 
binary logistic regression model. The results showed that, among asthmatics, PFASs were positively 
associated with estradiol levels and negatively associated with testosterone levels. However, only 
significant association was identified for PFNA and estradiol in control group. After controlling for 
hormone levels, associations between PFAS exposure and asthma were consistently stronger among 
children with higher than lower estradiol, with odds ratios (OR) for asthma ranging from 1.25 for PFOS 
(95% Confidence Interval [CI]: 0.90, 1.72) to 4.01 for PFDA (95% CI: 1.46, 11.06) among boys and 1.25 for 
PFOS (95% CI: 0.84, 1.86) to 4.16 for PFNA (95% CI: 1.36, 12.73) among girls. Notably, the interactions 
between estradiol and PFASs were significant for PFOS (p = 0.026) and PFNA (p = 0.043) among girls. 
However, testosterone significantly attenuated the association between PFOS and asthma across sex. 
In conclusions, our findings suggested that reproductive hormones amplify the association between 
PFASs and asthma among adolescents.
Asthma is an increasing new onset inflammatory disease that involves both intrinsic and environmental factors. 
Research indicates that perfluoroalkyl and polyfluoroalkyl substances (PFASs), types of persistent organic pollut-
ants, are associated with asthma and related outcomes, including airway hyperresponsiveness, increased serum 
levels of immunoglobulin E (IgE), and switched type 2 T helper cell (Th2) polarization1–4. Anderson-Mahoney 
et al. first identified the positive association between PFOA exposure and asthma4. US National Health and 
Examination Survey (NHANES) data showed that serum PFOA concentrations are positively associated with 
self-reported lifetime asthma prevalence5.
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Reproductive hormones seem to have a similar adverse effect on asthma development. Estradiol is reportedly 
involved in Th2 polarization, isotype switching to Ig E, mucus production, and cholinergic and histaminergic 
signaling in the nasal passageways6–8. In addition, despite inconsistent findings, a link between PFASs and sex 
steroid hormones has recently been widely reported9, 10.
To our knowledge, there are no published studies on the combined effects of PFASs and steroid hormones on 
asthma among adolescents, who are more developmentally vulnerable to the hormonal effects of environmental 
exposures than are adults. One possible reason for the dearth of literature in this area is lack of high quality study 
samples exposed to both PFASs and certain levels of reproductive hormones. Using data from The Genetics and 
Biomarkers study for Childhood Asthma (GBCA) in Taiwan, we tested the hypothesis that there were synergistic 
effects of the hormones and environmental pollution on asthma in children aged 10–15 years during 2009–2010 
from seven public schools in Northern Taiwan.
Methods
Study participants. The participants in our investigation were selected from the cohort of the Genetic and 
Biomarkers study for Childhood Asthma (GBCA) in Taiwan during 2009–2010. Detailed information about the 
cohort study is available elsewhere11. Briefly, the cases consisted of 231 children aged 10–15 years old from two 
hospitals in Taipei City, China, who had been diagnosed with asthma by a physician during the previous year. 
Control participants consisted of 225 children without a personal or family history of asthma from seven public 
schools in Taipei City. The cases and controls were matched on age and sex with an average response rate of 72.0%. 
After providing written informed consent, the adolescents and their parents were surveyed on demographics, 
environmental exposures and asthma outcomes. Physical examination measures, including height, weight, waist 
circumference, pulmonary function, and fasting serum were collected by trained technicians. The Institutional 
Review Board of the National Taiwan University Hospital Research Ethics Committee approved the methods 
of this study, which is also compliant with the principles outlined in the Helsinki Declaration (Declaration of 
Helsinki, 1990).
Key variables. Serum PFAS measurements, information about standards and reagents, sample preparation 
and extraction, instrumental analysis, quality assurance and quality control, and recovery experiments in the 
present study are detailed elsewhere11. In short, perfluorohexanesulfonate (PFHxS), perfluorooctane sulphonate 
(PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA) and perfluorodecanoic acid (PFDA) 
were measured from 0.5 mL of serum using Agilent high-performance liquid chromatography (HPLC) along 
with an Agilent 6410 Triple Quadrupole (QQQ) mass spectrometer (MS/MS) (Agilent, Palo Alto and Santa Clara, 
CA). The limit of quantification (LOQ) for PFOS, PFOA and PFNA was 0.03 ng/mL, 0.07 ng/mL for PFHxS, and 
0.1 ng/mL for PFDA. All measurements were repeated and the average of the two values was the concentration of 
each sample used for data analysis.
We performed serum testosterone and estradiol tests to determine reproductive hormone levels at an accred-
ited clinical laboratory. We measured reproductive hormones in serum by immunoluminometric assay with an 
Architect random access assay system (Abbott Diagnostics, AbbottPark, IL). The limit of detection (LOD) for 
estradiol and testosterone were 18 pmol/L and 0.23 nmol/L, respectively. We used 50 μL in analysis for testoster-
one and estradiol. The intra-assay and inter-assay coefficients of variation of these measurements were all below 
10%, and 15%, respectively. Of the blood samples, 67% were measured within 12 hours, and 33% between 12 and 
17 hours within collection.
Statistical analysis. We tested the data for normality (Q-Q plots) and homogeneity (Bartlett’s test for une-
qual variances), making appropriate transformations when necessary. Normal and homogenous continuous var-
iables are given as either the mean ± SD, or the median and quartile 1 (Q1)-quartile 3 (Q3). We used a t-test to 
compare the normally distributed continuous variables with asthma status, and the Wilcoxon rank-sum test to 
compare PFAS concentrations with asthma status due to skewed PFAS distributions. Sex hormones were natural 
log transformed for analyses. We tested relationships between categorical variables using contingency tables and 
the Chi-square test, and used multiple general linear models to estimate the relationship between reproductive 
hormone levels and a single PFAS exposure variable (adjusting for covariates).
We also employed multivariate linear regression analysis to explore the relationships between PFASs and 
reproductive hormones. Finally, to investigate the effect of hormone and PFAS interaction on asthma, we con-
ducted a two-level binary logistic regression model with children being the first-level unit and exposure being the 
second-level unit, and adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. At the 
child level, we modeled the logit of the prevalence of asthma by hormone level categories and other covariates. At 
the exposure level, the random coefficients were regressed on the pollutant level to explain the variations of the 
different level intercepts and coefficients. In the two-level binary logistic regression model, five PFASs—PFOA, 
PFOS, PFDA, PFHxS and PFNA—were considered key exposure variables. Covariates included were estradiol 
(lower than median, higher than median), age (years), sex (male, female), body mass index (BMI; kg/m2), paren-
tal education (less than and higher than high school), environmental tobacco smoke exposure (ETS, collected 
the smoking status of each participant’s adult household members and regular household visitors from current 
and past time), physical activity (at least 1 hour per day outside of physical education class), and month of survey 
(July-September, November-December). Statistical analyses were performed by the GLIMMIX procedure using 
SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA).
Results
Table 1 shows descriptive characteristics of the study population. Compared to children without asthma, male 
and younger children tended to have asthmatic symptoms (Table 1). In addition, levels of serum testosterone 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 899  | DOI:10.1038/s41598-017-01140-5
and estradiol were significantly higher among asthmatic children (p < 0.01). All median serum PFAS levels were 
significantly higher among asthmatic children than non-asthmatic children (p < 0.01). PFOS was higher in con-
centration than other PFASs, with a median of 28.91 ng/ml in non-asthmatics and 33.94 ng/ml in asthmatics.
Table 2 shows the results of multivariate linear regression analysis evaluating associations between PFASs 
and sex hormones, stratified by asthma category. Among participants without asthma, the only significant asso-
ciation was between PFNA and testosterone (β = 0.206; 95% CI: 0.002, 0.411). However, among asthmatics, four 
of five PFASs were significantly, positively associated with estradiol: PFOS (β = 0.001; 95% CI: 0.000, 0.003), 
PFOA (β = 0.054; 95% CI: 0.019, 0.089), PFDA (β = 0.096; 95% CI: 0.018, 0.174) and PFNA (β = 0.142; 95% CI: 
0.050, 0.234). In addition, two of five PFASs were significantly, negatively associated with testosterone: PFOS 
(β = −0.004; 95% CI: −0.005, −0.003) and PFOA (β = −0.036; 95% CI: −0.072, −0.001).
Tables 3 and 4 show interactions between PFASs and reproductive hormones, and their association with 
asthma. The association between individual PFAS exposure and asthma prevalence was consistently stronger 
among children with higher estradiol levels, with odds ratios (ORs) ranging from 1.06 to 1.69 for lower estradiol 
boys, 1.25 to 4.01 for higher estradiol boys, 0.65 to 3.54 for lower estradiol girls, and 1.25 to 4.16 for higher estra-
diol girls. Specifically, estradiol significantly enhanced the association of PFOS, PFDA and PFNA with asthma 
among adolescents (p < 0.10) (Table 4). However, testosterone modified the associations of only PFOS and 
asthma significantly, across sex (p < 0.05) (Table 3).
Discussion
This case-control study among 456 Taiwanese children aged 10–15 years is the first, to our knowledge, to explore 
the interaction between PFASs and reproductive hormones on asthma outcomes. Though inevitable confounding 
or other sources of bias cannot be ruled out, we found more significant associations between PFASs and hor-
mones among asthmatic than among non-asthmatic children. We also found that the associations between expo-
sure to each PFAS and the prevalence of asthma was consistently stronger among higher estradiol level children 
than among children with lower estradiol, with ORs estimated ranging from 1.06 to 1.69 for low estradiol boys, 
1.25 to 4.01 for higher estradiol boys, 0.65 to 3.54 for low estradiol girls, and 1.25 to 4.16 for high estradiol girls. 
These results suggested estradiol levels amplify the association between PFAS exposure and asthma.
Literature on this topic is sparse; a PubMed/Medline search yielded, no studies on the interaction between 
PFASs and reproductive hormones, and asthma. However, relevant studies about the relationship between both 
PFASs and asthma, and sex steroids and asthma are well documented2, 4, 5, 11.
Characteristic
With asthma Without asthma
p-Value(n = 231) (n = 225)
Age (years) 12.85 ± 1.67 13.61 ± 0.73 <0.001
Height (cm) 156.62 ± 10.43 159.83 ± 7.00 <0.001
Weight (kg) 49.83 ± 13.29 52.50 ± 13.21 0.033
BMI (kg/m2) 20.07 ± 3.89 20.40 ± 4.12 0.379
Sex*
 Boy 158 (60.77) 102 (39.23) <0.001
 Girl 73 (37.24) 123 (62.76)
Regular exercise*
 No 38 (41.76) 53 (58.24) 0.058
 Yes 193 (52.88) 172 (47.12)
Parental education*
 <high school 90 (51.14) 86 (48.86) 0.871
 ≥high school 141 (50.36) 139 (49.64)
Environmental tobacco smoke (ETS) exposure*
 No 138 (59.74) 93 (40.26) <0.001
 Yes 93 (41.33) 132 (58.67)
Month of survey*
 July-September 106 (40.46) 156 (59.54) <0.001
 November-December 125 (64.43) 69 (35.57)
PFOS (ng/mL)† 33.94 (19.59–61.10) 28.91 (14.06–42.02) 0.002
PFOA (ng/mL)† 1.16 (0.48–2.16) 0.52 (0.44–1.27) <0.001
PFDA (ng/mL)† 1.14 (0.89–1.48) 0.95 (0.76–1.15) <0.001
PFHxS (ng/mL)† 2.47 (1.25–4.26) 1.32 (0.59–2.79) <0.001
PFNA (ng/mL)† 1.00 (0.73–1.28) 0.83 (0.64–1.05) <0.001
Testosterone (nmol/L) (median) 11.47 ± 7.72 (13.90) 9.15 ± 8.99 (2.94) 0.003
Estradiol (pmol/L) (median) 178.67 ± 70.50 (166.72) 151.47 ± 65.05 (140.55) <0.001
Table 1. Characteristics of the study population (n = 456). Values are mean ± SD. *Values are number (%). 
†Values are median (Q1–Q3).
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For the association between PFASs and asthma, experimental research has reported a potential positive asso-
ciation. In a murine model of asthma, Fairley et al. reported a dose-response relationship between PFOA concen-
tration and the OVA-specific airway hyper reactivity response, as well as a pleiotropic cell response characterized 
by eosinophilia and mucin production2. Another in vitro experiment showed PFOA increased both histamine 
release and expression of pro-inflammatory cytokines, which induce mast cell-derived allergic inflammatory 
reactions3. In addition, one of our own previous studies showed PFOS exposure increased IL-4 and IL-10 but 
decreased IL-2 and IFN-γ secretion, meaning hosts’ immunity favors a T(H)2-like state1, 12.
Evidence from epidemiologic studies also supports associations between environmental PFASs and asthma 
among adolescents. In a cross-sectional study of 566 community-dwelling participants with prolonged PFOA 
exposure through contaminated drinking water, Anderson-Mahoney et al. found an association between PFOA 
exposure and asthma4. Specifically, asthma prevalence increased among participants exposed to PFOA compared 
Without asthma(n = 225) With asthma(n = 231)
Testosterone (nmol/L) Estradiol (pmol/L) Testosterone (nmol/L) Estradiol (pmol/L)
PFOS
−0.002 0.002 −0.004 0.001
(−0.008, 0.003) (−0.006, 0.004) (−0.005, −0.003) (0.000, 0.003)
PFOA
0.064 0.057 −0.036 0.054
(−0.090, 0.219) (−0.011, 0.125) (−0.072, −0.001) (0.019, 0.089)
PFDA
−0.194 0.053 −0.042 0.096
(−0.484, 0.097) (−0.076, 0.183) (−0.122, 0.037) (0.018, 0.174)
PFHxS
−0.004 0.025 −0.001 0.001
(−0.073, 0.065) (−0.006, 0.056) (−0.006, 0.003) (−0.004, 0.005)
PFNA
−0.341 0.206 −0.025 0.142
(−0.804, 0.121) (0.002, 0.411) (−0.119, 0.070) (0.050, 0.234)
Table 2. Association between PFASs (ng/mL) and ln-(sex hormones) using multivariate linear regression 
analysis by asthma category. All models are adjusted for age, sex, body mass index, parental education, 
environmental tobacco smoke exposure, physical activity, and month of survey. Coefficient (β) and 95 
confidence intervals (CI) represent the change in ln-(sex hormone) levels for each 1 ng/mL increase in PFAS 
concentration.
Low testosterone High testosterone Interaction
OR (95% CI)b OR (95% CI) b P-value
Boys
PFOS
2.54 1.04 0.005
(1.40, 4.60) (0.87, 1.25)
PFOA
2.82 2.42 0.660
(1.60, 4.97) (1.47, 3.99)
PFDA
1.71 3.16 0.339
(0.75, 3.90) (1.21, 8.25)
PFHxS
2.12 1.43 0.165
(1.34, 3.35) (0.99, 2.07)
PFNA
2.05 4.52 0.272
(0.75, 5.58) (1.59, 12.84)
Girls
PFOS
1.32 0.58 0.010
(0.88, 1.99) (0.36, 0.93)
PFOA
2.88 3.16 0.842
(1.39, 5.97) (1.47, 6.78)
PFDA
1.24 1.37 0.845
(0.60, 2.56) (0.63, 3.02)
PFHxS
1.62 2.27 0.334
(1.08, 2.45) (1.29, 3.99)
PFNA
1.15 4.25 0.121
(0.39, 3.37) (1.20, 15.03)
Table 3. Interaction effects of PFASs (ng/mL) and testosterone category on asthma, by sexab. alow vs high 
grouped according to median testosterone level. bAll models adjusted for age, sex, body mass index, parental 
education, environmental tobacco smoke exposure, physical activity, and month of survey.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 899  | DOI:10.1038/s41598-017-01140-5
to the general U.S. population (SPR = 1.82, 95% CI: 1.47, 2.25). Our present study also tested the associations 
between PFAS concentrations and asthma and observed positive associations among Taiwanese children, with the 
exception of PFOS, which was positively associated with asthma with adjusted OR among those with the highest 
versus lowest quartile of PFASs exposure ranged from 1.81 (95% CI: 1.02, 3.23) for PFDoA to 4.05 (95% CI: 2.21, 
7.42) for PFOA11. Recently, Smit et al. used meta-analysis to explore associations between contaminants meas-
ured in serum of pregnant women and both asthma and eczema among school-age children in the INUENDO 
birth cohort13. They applied principal components analysis and found the PC5 score, dominated by PFOA, was 
negatively associated with current wheezing (OR = 0.64; 95% CI: 0.41–0.99) in 612 samples from Ukraine. This 
inconsistent finding may result from the interaction between PFASs and reproductive hormones. Further, adoles-
cents may be more susceptible to exogenous and endogenous hormone variation than their adult counterparts. 
The results showed higher PFAS concentrations decreased testosterone and increased estradiol in adolescents 
significantly, but no such significant association was identified among their adult counterparts association14, 15.
There is also clear evidence that reproductive hormones influence asthma development and severity. 
Reproductive hormones have been seen to affect cholinergic and histaminergic signaling in the nasal passage-
ways, dissociation of endothelial NO synthase (an indicator of airway inflammation), prostaglandin synthesis 
and cGMP modulation of airway smooth muscle, and changes in immune response modulation8. In addition, 
research shows that estradiol or progesterone may skew the immune response toward Th26, isotype switching to 
immunoglobulin E7, and mast cell degranulation16 in experimental studies. However, testosterone either tilts the 
response to Th1 or suppresses inflammation17, 18. Giro´n-Gonza´lez reported higher secretion of Th1 cytokines 
IFN-γ and IL-2 in lymphocytes stimulated with phytohemagglutinin from males than females17. A 2012 epide-
miologic study confirmed higher prevalence of asthma among males than females prior to the onset of puberty8. 
However, female post-puberty asthma incidence is double that of males, and menopause is associated with accel-
erated lung function decline and increased new-onset asthma19, 20. Furthermore, menarche is also an important 
factor in women developing asthma21. Macsali reported women with early menarche (before age 10 years) have 
lower lung function and more asthma compared with women with later menarche. Thus, all the above results 
suggest that estradiol is a risk factor for asthma development, whereas testosterone is protective.
The way in which PFAS and sex hormones modulate the underlying biological mechanisms remains unclear. 
One possible explanation is that systemic inflammation, a widely known effect of PFASs, dictates emergence and 
development of asthma. It is thought that PFASs have an effect on most steps of allergic sensitization: type 2 T 
helper cell (Th2) polarization1, isotype switching to immunoglobulin E1, 2, and mast cell degranulation3. TH1/
TH2 polarization toward TH2 responses is common among atopy diseases22, and IgE is involved in mediating 
type 1 hypersensitivity reactions, including asthma23. In addition, mast cells could release the major mediators of 
acute hypersensitivity (e.g. histamine, cysteinyl leukotrienes), an obligatory event in allergic reactions24.
An increasing number of studies have shown that endogenous estradiol also can skew the immune response in 
favor of Th26, isotype switching to immunoglobulin E7, and mast cell degranulation16, and that these changes can 
Low estradiol High estradiol Interaction
OR (95% CI) b OR (95% CI) b P-value
Boys
PFOS
1.06 1.25 0.407
(0.87, 1.30) (0.90, 1.72)
PFOA
1.85 2.93 0.214
(1.12, 3.06) (1.64, 5.24)
PFDA
1.21 4.01 0.060
(0.60, 2.46) (1.46, 11.06)
PFHxS
1.47 1.62 0.741
(1.00, 2.15) (1.01, 2.60)
PFNA
1.69 3.79 0.289
(0.57, 5.00) (1.31, 10.96)
Girls
PFOS
0.65 1.25 0.026
(0.42, 0.99) (0.84, 1.86)
PFOA
3.54 2.56 0.486
(1.61, 7.79) (1.27, 5.12)
PFDA
0.76 1.78 0.176
(0.27, 2.20) (0.94, 3.35)
PFHxS
2.39 1.65 0.281
(1.39, 4.12) (1.07, 2.55)
PFNA
0.82 4.16 0.043
(0.26, 2.61) (1.36, 12.73)
Table 4. Interaction effects of PFASs (ng/mL) and estradiol category on asthma, by sexab. alow vs high grouped 
according to median estradiol level. bAll models adjusted for age, sex, body mass index, parental education, 
environmental tobacco smoke exposure, physical activity, and month of survey.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 899  | DOI:10.1038/s41598-017-01140-5
result in bronchial epithelium inflammation, fibrosis and airway constriction, and ultimately asthma. As PFASs 
and estradiol are both associated with increasing inflammation, and asthma is an inflammatory disease of the air-
ways that involves both intrinsic and environmental factors that promote inflammation in bronchoalveolar-lavage 
fluid or pulmonary secretions25, we hypothesize that adolescents with higher estradiol would be more susceptible 
to the inflammatory effects of PFAS exposure, leading to elevated asthma prevalence.
Finally, PFASs, as well as a variety of endocrine disrupting chemicals, have reportedly affected estrogen syn-
thesis, release, and function. Previous studies reported that PFASs affect enzyme synthesis and steroidogenicity, 
combine with estrogen receptors (ER) easily, and disrupt the reproductive axis26–29. Du et al. reported PFOA and 
PFOS could enhance ER-transactivation in the presence of 17β-estradiol while having direct binding affinity for 
ER in the absence of 17β-estradiol26, 27. ER has been demonstrated on human bronchial epithelial cells and binds 
respective hormones that crosstalk with an array of cellular signaling networks30. Thus, PFASs and estradiol may 
have a synergistic effect on the underpinnings of asthma development.
One interesting finding shows that the significant interaction on asthma was found for sex steroid hormones 
with PFOS, but not with PFOA, which indicates that PFOS is more likely to produce joint effect with hormones 
on atopic diseases. The reasons differences between PFOS and PFOA are not clear but may be associated with the 
PFASs concentrations. In present study, the serum concentrations of PFOS were 33.94 ng/mL in asthmatics and 
28.91 ng/mL in children without asthma, which were about 30-fold higher than the levels of PFOA (1.16 ng/mL 
in asthmatics and 0.52 ng/mL in children without asthma, respectively). In addition, some studies also reported 
the differences of toxicological response in vivo exposed to PFOS and PFOA. Recently, Kang et al. investigated the 
endocrine-related effects of PFOA and PFOS using in vitro estrogen receptor (ER) and androgen receptor (AR) 
transactivation assays and steroidogenesis assay31, and the results showed that the gene expression of cyp11b2 
related to corticoid biosynthesis was significantly increased by only PFOS. It is known that CYP11B2 is an enzyme 
involved in the biosynthesis of aldosterone, which play a key role in the development of atopy diseases including 
asthma32. However, as the agonists for peroxisome proliferator-activated receptors (PPARs) signaling pathway33, 
Takacs and Abbott conducted a study to characterize the differential activation of mouse and human PPAR-α, 
PPAR-β, and PPAR-γ, and the results indicated that PFOA had more trans-activity than PFOS with both the 
mouse and human PPAR isoforms34. Based upon these types outcomes in the above-cited studies, future studies 
will need to be undertaken to explore the mechanism underlying the difference effects between PFOS and PFOA.
Although this study provides new information on the influence of PFASs’ and reproductive hormones’ com-
plex interaction effects on asthma among children and adolescents, there are some limitations that should be 
addressed. First, establishing causal relationships between PFAS exposure and asthma outcomes is not possible 
due to the cross-sectional nature of the study. Second, the asthma cases and controls were recruited from hospitals 
and schools, respectively, making selection bias and uncontrolled confounding possible.
In the current study, we demonstrated the additive effects of PFAS and reproductive hormones on asthma in 
puberty, an important developmental period regarding asthma. As previously noted, males experience more cases 
of asthma until the onset of puberty, when the sex distribution of asthma is reversed due to the huge fluctuations 
in sex hormone levels at the onset of puberty. Thus, it is important to research the pathogenesis of and risk/pro-
tective factors for asthmatic children during this sensitive developmental period.
In conclusion, our results indicate that an increase in PFASs concentration was associated with asthma among 
adolescents, and this association seems stronger in those with higher estradiol levels. Our study is the first step 
toward understanding how PFAS exposure and hormones interact to affect asthma. The results of this research 
are consistent with the hypothesis that the effects of both environmental and endogenous estrogens together will 
determine asthma status.
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